Interaction of nogalamycin with chromatin.
Number of available nogalamycin binding sites in Sarcoma-180 chromatin is less than that present in Sarcoma-180 DNA. Gradual removal of proteins from chromatin by salt leads to increase in available drug binding sites, without appreciable alteration in binding affinity. Histones restrict the accessibility of nogalamycin to chromosomal DNA, whereas high mobility group (HMG) proteins have no effect. Association of histone H1 with chromosomal DNA has a more marked inhibitory effect on nogalamycin binding than other types of histones. Chromosomal protein induced conformational change in DNA appears to be the main factor in determining the availability of strong binding sites.
D002843:Chromatin / Q000378:metabolism*; D002868:Chromosomal Proteins, Non-Histone / Q000494:pharmacology; D003630:Daunorubicin / Q000031:analogs & derivatives*; D004347:Drug Interactions; D009621:Nogalamycin / Q000378:metabolism*; D011485:Protein Binding
D002843:Chromatin; D002868:Chromosomal Proteins, Non-Histone; D009621:Nogalamycin; D003630:Daunorubicin